LON:BVXP

Bioventix Interim Earnings Results & Report

Bioventix logo
GBX 1,896.55 -53.45 (-2.74%)
As of 11/20/2026 11:53 AM Eastern

Bioventix reported Interim earnings on March 30, 2026. The company reported EPS of GBX 69.38, while revenue was £6.16 billion.

Earnings Announcement Details

Quarter
Interim
Report Date

Bioventix EPS Results

Actual EPS
GBX 69.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioventix Revenue Results

Actual Revenue
£6.16 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioventix Interim Earnings FAQ

Bioventix (LON:BVXP) reported earnings of GBX 69.38 per share for Interim. The report was announced on Monday, March 30, 2026.

Bioventix reported revenue of £6.16 billion for Interim.

Bioventix Earnings Headlines

Bioventix : Posting of Annual Report and Notice of AGM
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Bioventix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventix and other key companies, straight to your email.

About Bioventix

Bioventix (LON:BVXP) creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

View Bioventix Profile